CD Biosynsis is a synthetic biology company that combines a multidisciplinary team with an established technology platform to provide tools and strategies for efficient biosynthesis. Its offerings support research and development across gene, protein, cell, and metabolic engineering. Products include genome-editing and CRISPR tools, gene assembly and editing reagents, cell lines, gRNA plasmids, and cell-free expression resources. The company also supplies protein-expression materials, unnatural amino acids, lipids, bioactive small molecules, assay kits, antibodies, probes, and other biochemical and molecular biology reagents.

CD Biosynsis provides services spanning custom DNA and RNA synthesis, DNA variant libraries, genome synthesis and assembly, and gene editing using CRISPR, TALEN, RNA interference, and base-editing approaches. Its protein services include design, directed evolution, expression, purification, production, modification, characterization, and high-throughput screening. Additional capabilities include strain and cell development, genetic engineering, inducible expression systems, metabolic engineering, and pathway design. The company also lists platform development in areas such as microfluidics, nanotechnology, omics, bioinformatics, and precision fermentation, serving researchers seeking integrated tools and services for biosynthesis and biotechnology development.